OUR COMPANY
Driven by science. Guided by purpose.
Taran Therapeutics is a precision inflammation and immunology company advancing investigational therapies for cancers and immune-driven diseases with high unmet need. We build on established science and move promising programs forward with focus, rigor, and urgency. Both our clinical-stage biologic agents have been and are being clinically tested and our lead candidate, Lenzilumab (LENZ), is initiating a Phase 3 trial for patients who have treatment-naive Chronic MyeloMonocytic Leukemia.
OUR MISSION
More life with the people who matter.
Our mission is to give our patients longer and better lives with the people they love.
We strive to build therapies for conditions of the highest unmet need, with our current focus on blood cancers and immune-driven diseases.
OUR VALUES
What Moves Us Forward.
Disciplined Execution.
We spend capital carefully and build with a focused, lean approach.
Biology before dogma.
We go where the mechanism points.
Rigor over hype.
We report what the data show, including when re-analysis changes a number.
Patients first. Urgently.
We treat time as the scarce resource it is, moving data, decisions, and trials forward.
OUR NAME
Rooted in memory, strength,
and purpose.
Taran was the name of a Welsh cob horse born during a thunderstorm and raised by our founder’s late wife, a proud Welsh woman. Meaning “thunder” in Welsh, the name honors her life and reflects the beauty, strength, and enduring spirit she embodied.
For our company, Taran represents an unstoppable force: the determination to move promising science forward and create better possibilities for patients.
Leadership
OUR TEAM
.png)
Board Member
Michael Schuster
